Consequently, only the last value of OD = 3·5 was maintained in each dilution series, while the previous maximum determinations were omitted (Fig. 1b). Subsequently, all OD values were divided by 3·6, which is just higher than the maximum selleck OD of 3·5. The value of 3·6 was chosen to transform the OD data to

values above 0, but below 1, as required for the subsequent logistic transformation, y’ = ln[y/(1–y)], as illustrated in Fig. 1c. A background level of OD = 0·15 was observed, and values below the corresponding logistically transformed value of −3·135 were omitted from further analysis. A linear regression was fitted to the remaining data points and dilution factors were compared at 50% of the maximum OD of 3·5, i.e. at OD = 1·75 (equal to a transformed value of −0·056), as indicated in Fig. 1d. In this example, the dilution factor check details of the calibrator serum was 24·911 = 30·1 while the dilution factor of the donor serum was 22·397 = 5·3, and hence the control serum was diluted 30·1/5·3 = 5·7 times more than the donor serum. Consequently, the functional activity of the MBL pathway of the donor was 100%/5·7 = 17·5% of the activity of the control serum. In order to determine the normal level of activity for the three pathways of complement, sera from 150 healthy Danish blood donors were analysed using the methods described in the Materials and methods

section. Complement activity of the AP and the CP was measured in all donors, and the activity data followed a normal distribution (AP: W = 0·99, P = 0·25;

CP: W = 0·99, P = 0·17, Shapiro–Wilk test) (Fig. 2a). The mean percentage activity level for the AP was 91% (range 54·8–129·2%) and for the CP was 101% (range 57·4–161·9%) (Fig. 2b). The lower cut-off value of normal AP and CP functional pathway activity was defined as the mean – 1·96 × standard deviation (SD), resulting in a lower cut-off value of normal pathway activity for the AP at 59% and at 61% for CP, respectively. In contrast, the MBL pathway activity data did not follow a normal distribution (P = 0·003; Shapiro–Wilk test). The data showed Axenfeld syndrome a large variation with a bimodal distribution (Fig. 2a). The mean activity for the MBL pathway was 66·3% (range: 0–209·1%) (Fig. 2b). The MBL activity of the donor sera was correlated highly to the serum MBL concentration (r2 = 0·70, P < 0·0001) (Fig. 3). Given the relatively high frequency of individuals with MBL deficiency in the general population, it is somewhat troublesome to define a normal MBL activity range without taking into consideration individuals with somatic mutations in the MBL2 gene leading to MBL structures with very low binding avidities. In an attempt to define a meaningful cut-off value for normal MBL pathway activity, 22 donors with MBL pathway activities between 0 and 43% were MBL genotyped (Table 1).